Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a decrease of $1.2 million or 50% compared to $2.4 million in 2024, primarily due to lower participant demand for clinical trials and reduced contract manufacturing services [11][12] - General and administrative expenses increased to approximately $12 million in 2025 from $10.3 million in 2024, reflecting a 17% rise due to increased personnel costs [12] - Research and development expenses rose to approximately $12 million in 2025 from $8.1 million in 2024, marking a 48% increase driven by personnel costs and technology transfer expenses [13][14] - The net loss increased to approximately $22.7 million in 2025 from $16 million in 2024, a rise of 41% [14] Business Line Data and Key Metrics Changes - Clinical trial revenue for 2025 was $1 million, down from $1.4 million in 2024, while contract manufacturing revenue decreased from $0.5 million to $0.2 million [11][12] Market Data and Key Metrics Changes - The company has secured $15 million in new capital from institutional investors, with a potential second tranche of $15 million contingent on meeting certain milestones [3][4] - The HLHS program has been granted rare pediatric disease designation by the FDA, making it eligible for priority review vouchers (PRVs) upon approval of a BLA [7] Company Strategy and Development Direction - The company aims to pursue a robust partnering strategy across all development programs to accelerate time to market and leverage resources from larger organizations [4][5] - The focus is on the HLHS program with a near-term pathway to potential approval, and the company plans to initiate a pivotal phase 2 registrational study for pediatric dilated cardiomyopathy (PDCM) [8][10] - The company is also exploring opportunities in Alzheimer's disease and age-related frailty, with plans to seek licensing partners for these initiatives [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming pivotal data for HLHS and the strengthening of the balance sheet, indicating a potentially exciting time for the company [18] - The CEO highlighted the importance of strategic partnerships and the potential for significant financial outcomes from PRVs [7][18] Other Important Information - The company anticipates that existing cash and cash equivalents will fund operations into Q4 of 2026 following a recent private placement [15] - The company is actively engaged in clinical trials and has made significant progress in stem cell research, with multiple patents issued globally [16][17] Q&A Session Summary Question: Commercial perspectives for laromestrocel manufacturing - Management confirmed the potential for a separate PRV for PDCM and emphasized the priority of manufacturing and CMC for future growth [22][23] Question: Non-dilutive capital sources for Alzheimer's disease - Management indicated that seeking licensing partners for Alzheimer's disease and age-related frailty is a priority, with preliminary conversations already set up [24] Question: Timeline for BLA filing for HLHS - Management stated that if data is positive in Q3 2026, they would aim for a rolling submission for the BLA, targeting submission in 2027 [28][31] Question: Pediatric dilated cardiomyopathy program details - Management outlined plans for a hierarchical composite endpoint in the PDCM trial, aiming to reduce heart transplant needs and hospitalization [40][42] Question: Strategy for laromestrocel in female sexual dysfunction - Management sees this indication as a ripe opportunity for partnerships, addressing a significant unmet need in women's health [46][50]

A Regenerative Medicine Company Stem cell therapies addressing life threatening conditions in the most vulnerable populations - children and the elderly Investor Presentation Nasdaq (LGVN) │ March 2026 Forward Looking Statements Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management's current expectations, assumptions, and estimates of f ...

As filed with the Securities and Exchange Commission on February 5, 2026. Registration No. 333-293150 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ERNEXA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 31-1103425 (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

Core Perspective - The article discusses a strategic partnership among Cytora Therapeutics, Made Scientific, and Zeo ScientifiX to advance and commercialize an innovative oral mucosal stem cell therapy for non-healing diabetic foot ulcers and other indications in the U.S. market [1][2][3] Group 1: Partnership Objectives - The partnership aims to commercialize Cytora's novel therapeutic under Florida's new stem cell law, allowing non-FDA-approved stem cell therapies for wound care, pain, and orthopedic conditions [2][4] - The collaboration will initiate U.S. FDA Phase 2b clinical trials to obtain FDA approval for the therapy [2][4] Group 2: Roles and Responsibilities - Cytora will manage clinical and regulatory development while granting manufacturing rights for its product [3] - Made Scientific will act as the exclusive U.S. manufacturing partner, handling GMP manufacturing and quality control from its facility in Princeton, New Jersey [3] - Zeo will serve as the exclusive U.S. commercial partner, providing market access, distribution, and clinical site management [3] Group 3: Market Potential - The partnership will initially target diabetic foot ulcers, with an estimated 125,000 new patients annually in Florida, and plans to expand into additional therapeutic areas representing over 3.6 million annual cases [4] - The collaboration supports a U.S. FDA IND pathway for a Phase 2b clinical trial and future international regulatory submissions [4] Group 4: Technology and Clinical Data - Cytora's technology utilizes proprietary allogeneic human oral mucosal stem cells (hOMSCs), which have shown regenerative potential in clinical trials [5][7] - In a completed Phase 1/2a trial, Cytora's hOMSC200 demonstrated a favorable safety profile and significant efficacy in wound healing, achieving complete closure in diabetic patients with chronic ulcers [7]

Core Insights - MEDIPOST has secured an $8 million upfront payment for the joint commercialization of its stem cell therapy CARTISTEM in Japan, targeting knee osteoarthritis [1][2] - The partnership with Teikoku Seiyaku Co., Ltd. includes exclusive sales, distribution, and promotion rights for CARTISTEM in Japan, while MEDIPOST retains manufacturing rights [2][3] - CARTISTEM has been administered to over 35,000 patients since its regulatory approval in South Korea in 2012 and is designed to regenerate cartilage in knee osteoarthritis patients [4] Company Overview - MEDIPOST, founded in 2000, is a global stem cell therapy company with capabilities in discovery research, clinical development, and cell and gene therapy contract development and manufacturing [5] - Teikoku Seiyaku, established in 1848, focuses on transdermal drug delivery technology and has a mission to alleviate pain, with ongoing efforts in the orthopedic sector [6][7] Market Strategy - Teikoku Seiyaku plans to utilize its extensive orthopedic hospital and clinic network to promote CARTISTEM, aiming to address unmet medical needs in knee osteoarthritis treatment in Japan [3][6] - The company is expanding its medical representative division to enhance the promotion of CARTISTEM ahead of its approval [3]

Core Insights - Hemostemix Inc. presented data on its ACP-01 therapy, highlighting its strong safety profile and functional gains in treating conditions like chronic limb-threatening ischemia (CLTI), cardiomyopathy, and angina [1][4][12] Safety Profile - The safety profile of ACP-01 was demonstrated across more than 498 treated patients, with no cell-related complications reported [3][5] - Historical programs noted one non-related death and two responsive tachyarrhythmias, indicating a favorable safety outcome [5] Cardiovascular Efficacy - In patients with ischemic and dilated non-ischemic cardiomyopathy, ACP-01 showed a ~5% absolute increase in left ventricular ejection fraction (LVEF), translating to a 16-47% improvement in cardiac function depending on the subtype [4][12] - Significant improvements were observed in 6-minute walk tests, exercise capacity, and angina class at 3-6 months post-treatment [6][12] CLTI Treatment Outcomes - In no-option CLTI populations, ACP-01 was associated with a combined amputation/death rate of ~5% compared to ~40% in the control group over 12 months [12] - Wound-presenting patients exhibited significant healing responses compared to placebo [12] Florida Access Pathway - Under Florida SB 1768, physicians can offer autologous stem-cell therapies, including ACP-01, with informed consent and FDA-regulated manufacturing [12] - ACP-01 is now available in Florida outside of clinical trials, priced at US$37,000, excluding physician and clinic fees [12] Treatment Administration Process - The treatment process involves a blood draw, ex-vivo expansion of ACP-01 over 5 days, quality control, and local intramuscular injections on the 7th day [12] Future Steps - Hemostemix plans to schedule treatments in Florida and The Bahamas, where ACP-01 is permitted [11]

Financial Data and Key Metrics Changes - Revenues for the nine months ended September 30, 2025, were $0.8 million, a decrease of $1.0 million or 53% compared to $1.8 million in 2024, primarily due to decreased participant demand for the Bahamas registry trial and reduced demand for contract manufacturing services [22][24] - Net loss increased to approximately $17.3 million for the nine months ended September 30, 2025, from a net loss of $11.9 million for the same period in 2024, representing an increase of $5.4 million or 45% [26][27] - Cash and cash equivalents as of September 30, 2025, were $9.2 million, with the company anticipating this will fund operating expenses into late Q1 2026 [26][27] Business Line Data and Key Metrics Changes - Clinical trial revenue for the nine months ended September 30, 2025, was $0.7 million, a decrease of $0.3 million or 36% compared to $1.0 million in 2024, driven by decreased participant demand [23] - Contract manufacturing revenue for the same period was $0.2 million, a decrease of $0.6 million or 76% compared to $0.8 million in 2024, also due to reduced demand [24] Company Strategy and Development Direction - The company is focused on three key areas: delivering clinical trial results from ELPASO-2, securing necessary financial resources, and HLHS BLA preparedness [10][12] - The company aims to attract partners for the continued development and potential commercialization of Lomecel-B, particularly in HLHS and other indications [12][30] - The company has made operational decisions to extend its cash runway into late Q1 2026, pushing the potential full BLA filing from late 2026 into 2027 [27][28] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of establishing safety and efficacy through FDA-supported clinical studies as critical for building belief in the potential life-saving qualities of their therapies [7][9] - The company is optimistic about the potential for pivotal clinical data for HLHS and the first BLA submission, viewing this as an exciting time for both the company and its stakeholders [28][30] Other Important Information - The company has received five distinct FDA designations for its development programs, including orphan drug and fast track designations for HLHS [29][30] - The company is exploring opportunities for new contract manufacturing services clients to utilize excess capacity in its Miami cGMP facility [22][24] Q&A Session Summary Question: Business advisability of identifying potential partners for commercialization in rare conditions - Management indicated that they are exploring partnerships outside the US and are prepared to commercialize the product, recognizing the value of being close to pivotal study readouts [34][36] Question: Clarification on the primary endpoint for ELPASO-2 - Management discussed the importance of the composite endpoint, which includes all-cause mortality, transplant-free survival, and overall hospitalization, and emphasized the use of prior positive data to design meaningful endpoints [47][50] Question: Reasons for postponing the BLA submission timeline - Management explained that the full submission by the end of 2026 is unlikely due to operational decisions aimed at optimizing spending, but they remain committed to the database lock and trial conduct [52][55] Question: Impact of early success in similar therapies on Longeveron's value - Management acknowledged the significance of the HLHS program and the potential for high-value outcomes, while also recognizing the success of other cell therapies as a positive case study [65][67] Question: Importance of long-term follow-up data for payer conversations - Management highlighted the value of survival endpoints and long-term data from ELPASO-1 as important for future reimbursement discussions, although they could not predict its exact impact [68][70] Question: Exploration of expedited BLA pathways - Management confirmed ongoing discussions with the FDA regarding potential expedited pathways and emphasized the importance of the priority review voucher system for rare diseases [71][75]

Core Insights - Karolinska Development AB has invested SEK 7.5 million in BOOST Pharma's financing round, which totals SEK 15 million, aimed at advancing the clinical development of BT-101 for osteogenesis imperfecta [1][3][4] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101, a mesenchymal stem cell therapy for infants with osteogenesis imperfecta, a condition that leads to fragile bones and frequent fractures [2][3] - The financing will help BOOST Pharma accelerate its clinical program and work towards providing the first disease-modifying therapy for osteogenesis imperfecta [2] Clinical Development - Following positive results from the Phase 2 BOOSTB4 study, which demonstrated a reduction in fracture rate of over 75% in children with osteogenesis imperfecta, BOOST Pharma is preparing for a pivotal Phase 3 trial of BT-101 [3] - The BOOSTB4 trial indicated that BT-101 was safe and well-tolerated [3] Investment and Ownership - Karolinska Development's ownership stake in BOOST Pharma is 14% [4] - The financing round included equal participation from Industrifonden and Karolinska Development, highlighting collaborative investment efforts in the biopharmaceutical sector [3]

Core Viewpoint - BioRestorative Therapies, Inc. has announced a registered direct offering of 678,125 shares at $1.60 per share, alongside a concurrent private placement of unregistered warrants, aiming to raise approximately $1.085 million for clinical trials and development initiatives [1][2][3] Group 1: Offering Details - The offering price for the common stock is set at $1.60 per share, with the stock closing at $1.50 on October 3, 2025 [1] - The company will issue unregistered warrants to purchase up to 508,594 shares, representing 75% warrant coverage, with an exercise price of $2.75 per share [1] - The gross proceeds from the offering are expected to be $1.085 million before expenses, with the closing anticipated around October 8, 2025 [1][2] Group 2: Use of Proceeds - The net proceeds will be utilized for clinical trials related to the lead cell therapy candidate BRTX-100, pre-clinical research for the ThermoStem Program, and development of the biocosmeceuticals platform [2] - Additional funds will support general corporate purposes and working capital [2] Group 3: Company Background - BioRestorative focuses on developing therapeutic products using adult stem cells, with key programs targeting disc/spine disease and metabolic disorders [7] - The lead candidate, BRTX-100, is designed for non-surgical treatment of lumbosacral disc disorders and is currently in Phase 2 clinical trials [8] - The company is also developing therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [9] and operates a commercial BioCosmeceutical platform [10]

Core Insights - Longeveron Inc. has elected Dr. George Paletta, Jr. to its Board of Directors, bringing extensive experience in medicine and entrepreneurship to the company [2][3] - The company is focused on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, with a promising pipeline of stem cell therapies [2][6] Company Overview - Longeveron is a clinical stage biotechnology company that develops regenerative medicines to address unmet medical needs, with its lead product being laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy [6] - The company is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [6] - Laromestrocel has received five important FDA designations, including Orphan Drug designation and Fast Track designation for the HLHS program [6] Leadership and Expertise - Dr. Paletta is a recognized orthopedic surgeon and has significant experience in developing ambulatory surgical centers, having participated in the sale of two ASCs valued at nearly $1 billion [2][3] - He holds multiple patents in orthopedic and cardiovascular fields and has been involved in various start-up ventures, providing advisory roles [3][4] - Dr. Paletta's educational background includes a Doctor of Medicine from Johns Hopkins University and an MBA from Washington University in St. Louis [4]